01 April 2011
Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countriesEwa OrlewskaABCDEFG, Ioan AncutaB, Branimir AnicB, Catalin CodrenauB, Nemanja DamjanovB, Predrag DjukicB, Ruxandra IonescuB, Lubomir MarinchevB, Evgeny L. NasonovB, Tonu PeetsB, Sonja PraprotnikB, Rasho RashkovB, Jana SkoupaB, Witold TlustochowiczB, Malgorzata TlustochowiczB, Matija TomsicB, Tiina VeldiB, Jelena VojinovicB, Piotr WilandB
Med Sci Monit 2011; 17(4): SR1-13
Background: The aim of this study was to assess and compare patients’ access to biologic anti-RA drugs in selected Central and Eastern European (CEE) countries and to analyze the determinants of differences between countries.
Material/Methods: This is a multi-country survey study, based on a combination of desk research and direct contact with national RA stakeholders. Data was collected using a pre-defined questionnaire. Affordability was measured using an affordability index, calculated comparing the index of health care expenditures to the price index, using Poland as an index of 1.
Results: The percentage of patients on biologic treatment in 2009 was highest in Hungary (5% RA patients on biologic treatment), followed by Slovenia (4.5%), Slovakia (3.5%), Czech Republic (2.92%), Romania (2.2%), Estonia (1.8%), and Croatia, Serbia, Poland (below 1.5%). Infliximab, etanercept, adalimumab and rituximab were included in the reimbursement system in all countries, but abatacept and tocilizumab were included only in Slovakia. In Slovenia, public payer covered 75% of the price, and 25% is covered by supplementary health insurance; in Bulgaria public payer covered 50% of etanercept and adalimumab costs, and 75% of rituximab cost. In other countries, biologic drugs are reimbursed at 100%. Affordability index for biologic drugs was the lowest in Slovenia (0.4). In each country national guidelines define which patients are eligible for biologic treatment. Disease Activity Score (DAS28) of over 5.1 and failure of 2 or more disease-modifying anti-RA drugs, including methotrexate, are commonly used criteria.
Conclusions: The most important factors limiting access to biologic anti-RA treatment in the CEE region are macroeconomic conditions and restrictive treatment guidelines.
Keywords: Europe, Health Expenditures, Delivery of Health Care - economics, Costs and Cost Analysis, Biological Therapy, Arthritis, Rheumatoid - therapy, Antirheumatic Agents - therapeutic use, Health Planning Guidelines, Health Services Accessibility - economics
04 June 2022 : EditorialEditorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?
Med Sci Monit 2022; 28:e937371
27 Jun 2022 : Clinical ResearchAutomatic Identification of Depression Using Facial Images with Deep Convolutional Neural Network
Med Sci Monit In Press; DOI: 10.12659/MSM.936409
23 Jun 2022 : Clinical ResearchA Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...
Med Sci Monit In Press; DOI: 10.12659/MSM.936706
22 Jun 2022 : Clinical ResearchA Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...
Med Sci Monit In Press; DOI: 10.12659/MSM.937316
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996